167 related articles for article (PubMed ID: 38054365)
1. Associations of circulating immunomarkers with the efficacy of immunotherapy for primary hepatic carcinoma.
Liu S; Xu W; Shu H; Dai Y; Du Y; Liu Y; Huang L; Sun G
Cancer Med; 2023 Dec; 12(24):21830-21848. PubMed ID: 38054365
[TBL] [Abstract][Full Text] [Related]
2. Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.
Zheng L; Xiong A; Wang S; Xu J; Shen Y; Zhong R; Lu J; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
Front Immunol; 2023; 14():1094378. PubMed ID: 36776882
[TBL] [Abstract][Full Text] [Related]
3. Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: a superior prognostic factor of endometrial cancer.
Cong R; Kong F; Ma J; Li Q; Wu Q; Ma X
BMC Cancer; 2020 May; 20(1):464. PubMed ID: 32448185
[TBL] [Abstract][Full Text] [Related]
4. Can Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio at Day +100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?
Solmaz Medeni S; Acar C; Olgun A; Acar A; Seyhanlı A; Taskıran E; Sevindik OG; Alacacıoglu I; Piskin O; Ozcan MA; Demirkan F; Undar B; Ozsan GH
Clin Transplant; 2018 Sep; 32(9):e13359. PubMed ID: 30053318
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
[TBL] [Abstract][Full Text] [Related]
6. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Value of Inflammation Factors in Hepatocellular Carcinoma Patients with Hepatic Artery Interventional Treatments: A Retrospective Study.
Guo L; Ren H; Pu L; Zhu X; Liu Y; Ma X
Cancer Manag Res; 2020; 12():7173-7188. PubMed ID: 33061563
[TBL] [Abstract][Full Text] [Related]
8. A High Monocyte-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Advanced Gallbladder Cancer Receiving Chemotherapy.
Choi YH; Lee JW; Lee SH; Choi JH; Kang J; Lee BS; Paik WH; Ryu JK; Kim YT
Cancer Epidemiol Biomarkers Prev; 2019 Jun; 28(6):1045-1051. PubMed ID: 30842131
[TBL] [Abstract][Full Text] [Related]
9. The Clinicopathological and Prognostic Value of NLR, PLR and MLR in Non-Muscular Invasive Bladder Cancer.
Chen H; Wu X; Wen Z; Zhu Y; Liao L; Yang J
Arch Esp Urol; 2022 Jun; 75(5):467-471. PubMed ID: 35983820
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization.
Fan W; Zhang Y; Wang Y; Yao X; Yang J; Li J
PLoS One; 2015; 10(3):e0119312. PubMed ID: 25742141
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, or Monocyte-to-Lymphocyte Ratio in Endometrial Neoplasms: A Systematic Review and Meta-analysis.
Leng J; Wu F; Zhang L
Front Oncol; 2022; 12():734948. PubMed ID: 35651788
[TBL] [Abstract][Full Text] [Related]
12. Correlation of Prognostic Markers {CEA, Ca19.9, Neutrophil To Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR)} With Progression Free Survival (PFS) in Advanced/Metastatic Gallbladder Carcinoma.
Naik MD; Kataria SP; Kumar G; Singh R
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443542
[TBL] [Abstract][Full Text] [Related]
13. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.
Bilen MA; Martini DJ; Liu Y; Lewis C; Collins HH; Shabto JM; Akce M; Kissick HT; Carthon BC; Shaib WL; Alese OB; Pillai RN; Steuer CE; Wu CS; Lawson DH; Kudchadkar RR; El-Rayes BF; Master VA; Ramalingam SS; Owonikoko TK; Harvey RD
Cancer; 2019 Jan; 125(1):127-134. PubMed ID: 30329148
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.
Schobert IT; Savic LJ; Chapiro J; Bousabarah K; Chen E; Laage-Gaupp F; Tefera J; Nezami N; Lin M; Pollak J; Schlachter T
Eur Radiol; 2020 Oct; 30(10):5663-5673. PubMed ID: 32424595
[TBL] [Abstract][Full Text] [Related]
15. [Effect of preoperative monocyte-lymphocyte ratio on prognosis of patients with resectable esophagogastric junction cancer].
Zhou WJ; Wu J; Li XD; Wang Q; Ni XF; Jiang JT; Ji M; Wu CP
Zhonghua Zhong Liu Za Zhi; 2017 Mar; 39(3):178-183. PubMed ID: 28316215
[No Abstract] [Full Text] [Related]
16. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy.
Dharmapuri S; Özbek U; Lin JY; Sung M; Schwartz M; Branch AD; Ang C
Cancer Med; 2020 Jul; 9(14):4962-4970. PubMed ID: 32419290
[TBL] [Abstract][Full Text] [Related]
17. Preoperative Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio are Associated with the Prognosis of Group 3 and Group 4 Medulloblastoma.
Li K; Duan WC; Zhao HB; Wang L; Wang WW; Zhan YB; Sun T; Zhang FJ; Yu B; Bai YH; Wang YM; Ji YC; Zhou JQ; Liu XZ; Zhang ZF; Zhang ZY
Sci Rep; 2019 Sep; 9(1):13239. PubMed ID: 31519974
[TBL] [Abstract][Full Text] [Related]
18. Preoperative inflammatory markers as prognostic predictors after hepatocellular carcinoma resection: data from a western referral center.
Silva JPM; Coelho FF; Cassenote AJF; Jeismann VB; Fonseca GM; Kruger JAP; de Meira Júnior JD; Nahas SC; Herman P
BMC Surg; 2022 Sep; 22(1):329. PubMed ID: 36056350
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy.
Yang M; Zhang J; Wei D; Yu T; Chen Z; Liu X; Zhu H
BMC Cancer; 2024 Feb; 24(1):196. PubMed ID: 38347460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
